Friday 6 November 2026
Export ILMN’s income statement to Excel — free account
Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024.
- Revenue
- +4.15%
- EPS
- +49.0%
- Free cash flow
- +49.8%
- Total debt
- +80.0%
Quarter to September 2026, against a year earlier
212.80
4.80
+2.31%
Follow ILMN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 6 | 6 | 8 |
+8 more TTM periods Free account |
| 32.39% | 32.38% | 33.82% | 33.36% | ||
| 13.78% | 12.95% | 13.39% | 13.13% | ||
ROIC |
16.70% | 17.46% | 17.69% | 19.55% | |
Return on Tangible Assets |
34.29% | 41.23% | 44.27% | 34.51% | |
Average Days of Receivables |
59.36 | 62.07 | 61.32 | 71.77 | |
Free Cash Flow per Share |
7.00 | 6.17 | 6.37 | 6.01 | |
Free Cash Flow |
1,057.00 | 931.00 | 974.00 | 931.00 | |
Capital Expenditures |
(173.00) | (164.00) | (154.00) | (148.00) | |
| Other line items | |||||
Cash ROIC |
16.86% | 16.94% | 18.30% | 15.93% | |
Accounts Receivable Turnover |
6.19 | 6.13 | 6.11 | 5.47 | |
Accounts Payable Turnover |
6.35 | 7.02 | 6.99 | 6.39 | |
Inventory Turnover |
2.32 | 2.51 | 2.59 | 2.65 | |
Average Days of Payables |
60.33 | 55.60 | 53.58 | 59.47 | |
Days of Inventory on Hand |
166.98 | 152.04 | 150.18 | 139.76 | |
Tax Rate |
(0.15) | (0.19) | (0.20) | (0.22) | |
Research and Development Expense of Revenue |
21.49% | 21.37% | 21.74% | 22.27% | |
Selling, General and Administrative Expense of Revenue |
24.99% | 25.15% | 24.83% | 25.01% | |
Share Based Compensation of Revenue |
5.95% | 5.92% | 5.96% | 6.33% | |
Interest Coverage |
9.81 | 8.92 | 8.52 | 7.99 | |
Operating CF/Net income |
1.37 | 1.33 | 1.32 | 1.27 | |
Depreciation/Fixed assets |
0.38 | 0.37 | 0.36 | 0.36 | |
Capex/Depreciation |
(0.62) | (0.60) | (0.57) | (0.55) | |
Revenue per Share |
30.05 | 29.76 | 28.71 | 28.02 | |
Operating CF per Share |
8.15 | 7.25 | 7.37 | 6.96 | |
Capex per Share |
(1.15) | (1.09) | (1.01) | (0.95) | |
Capex to Sales |
0.04 | 0.04 | 0.04 | 0.03 |
Columns are period end dates · fundamentals updated 5 Nov 2026